See more : Aker Technology Co., Ltd (6174.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of 23andMe Holding Co. (ME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 23andMe Holding Co., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Neptune Wellness Solutions Inc. (NEPT.TO) Income Statement Analysis – Financial Results
- XcelPlus International, Inc. (XLPI) Income Statement Analysis – Financial Results
- Starts Publishing Corporation (7849.T) Income Statement Analysis – Financial Results
- PT Sumber Tani Agung Resources Tbk (STAA.JK) Income Statement Analysis – Financial Results
- AEON Biopharma, Inc. (AEON) Income Statement Analysis – Financial Results
23andMe Holding Co. (ME)
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 219.64M | 299.49M | 271.89M | 243.92M | 305.46M | 440.90M |
| Cost of Revenue | 120.26M | 164.99M | 138.95M | 126.91M | 168.03M | 257.91M |
| Gross Profit | 99.38M | 134.50M | 132.95M | 117.01M | 137.43M | 182.99M |
| Gross Profit Ratio | 45.25% | 44.91% | 48.90% | 47.97% | 44.99% | 41.50% |
| Research & Development | 205.36M | 222.60M | 189.38M | 159.86M | 181.28M | 140.53M |
| General & Administrative | 148.33M | 115.98M | 97.38M | 99.15M | 59.39M | 50.29M |
| Selling & Marketing | 85.60M | 119.93M | 100.34M | 43.20M | 110.52M | 190.85M |
| SG&A | 205.74M | 235.91M | 197.72M | 142.35M | 169.91M | 231.24M |
| Other Expenses | 9.63M | -93.00K | -83.00K | 1.32M | 1.34M | 0.00 |
| Operating Expenses | 420.73M | 458.51M | 387.10M | 302.20M | 351.19M | 371.77M |
| Cost & Expenses | 540.99M | 623.50M | 526.05M | 429.12M | 519.22M | 629.68M |
| Interest Income | 14.33M | 9.68M | 277.00K | 1.58M | 6.24M | 5.25M |
| Interest Expense | 0.00 | 0.00 | 277.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.48M | 36.50M | 26.15M | 20.25M | 22.25M | 9.90M |
| EBITDA | -291.87M | -291.94M | -228.01M | -164.95M | -191.51M | -173.63M |
| EBITDA Ratio | -132.89% | -96.00% | -95.99% | -67.62% | -47.72% | -40.57% |
| Operating Income | -321.36M | -324.01M | -254.15M | -185.20M | -213.76M | -188.78M |
| Operating Income Ratio | -146.31% | -108.19% | -93.48% | -75.92% | -69.98% | -42.82% |
| Total Other Income/Expenses | -345.28M | 9.58M | 33.18M | 1.58M | -37.11M | 5.25M |
| Income Before Tax | -666.63M | -314.43M | -220.97M | -183.62M | -250.86M | -183.53M |
| Income Before Tax Ratio | -303.51% | -104.99% | -81.27% | -75.28% | -82.13% | -41.63% |
| Income Tax Expense | 73.00K | -2.77M | -3.48M | -255.00K | 38.45M | 9.74M |
| Net Income | -666.70M | -311.66M | -217.49M | -183.36M | -289.31M | -183.53M |
| Net Income Ratio | -303.55% | -104.06% | -79.99% | -75.17% | -94.71% | -41.63% |
| EPS | -1.40 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| EPS Diluted | -28.01 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| Weighted Avg Shares Out | 475.98M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
| Weighted Avg Shares Out (Dil) | 23.80M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
Metals Creek Resources Corp. Closes First Tranche of Flow-Through Private Placement Financing - Secures Drill for Next Phase of Tillex Copper Project Drilling
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe cuts 40% of staff in restructuring
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
23andMe reports sales decline day after announcing plans to cut 40% of workforce
23andMe's stock turns lower after company posts its latest quarterly loss
23andMe to cut 40% of its workforce as it looks to stablise the business
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
Source: https://incomestatements.info
Category: Stock Reports